2016-08-11 20:18:12 UTC

Share Your Thoughts on Quality Measures That Will Work for You

Aug. 16, 2016

It's important that AGA-developed quality measures meet the needs of practicing GIs and hepatologists.

In continuing its leading measures development work, AGA has developed two new processes that allow you to submit measures concepts that you would like us to consider for further development and implementation in national reporting programs. We are also looking for you to offer your expertise and provide feedback on newly developed and existing measures.

Call for GI and Hepatology Measures
As a part of its measures prioritization process, AGA requests that interested parties submit potential new measures concepts. Proposed measures concepts will be reviewed by the AGA Quality Measures Committee and considered for future measures development. This annual call for measures will occur on a rolling basis and will close Aug. 31 at 4 p.m. ET each year for consideration in the next year’s development cycle.

AGA will publish a response to each call for measures on the AGA website after review and evaluation by the AGA Quality Measures Committee no later than Dec. 31, 2016. Take this survey to share your thoughts on measures that could benefit your practice of medicine.

Share Your Thoughts on Proposed Measures
AGA is also seeking comments from members, providers, consumers, the public, private purchasers and other stakeholders on proposed measures. The 30-day public comment period for the following new measures are currently open and will close Sept. 8, 2016, at 4 p.m. ET

  • Patients with cirrhosis, surveillance for developing hepatocellular carcinoma. View measure and comment.  
  • Endoscopy/Barrett’s esophagus surveillance: Systematic biopsies during surveillance esophagoscopy or esophagogastroduodenoscopy (EGD) in patients with Barrett’s esophagus without dysplasia — Adequacy of surveillance. View measure and comment.
  • Endoscopy/Barrett’sesophagus surveillance: Esophagoscopy or EGD interval for patients with non-dysplastic Barrett’s esophagus — Avoidance of Inappropriate Use. View measure and comment.

All comments will be reviewed and considered by the AGA Quality Measures Committee and responses will be published on the AGA website after the review is complete, no later than Dec. 31, 2016. AGA is particularly interested in your feedback in the following areas:

  • Usefulness of the measure in assessing and improving quality of patient care. 
  • Whether the measure accurately assesses a provider’s performance and any unintended consequences should the measure be implemented.
  • Whether data elements are readily available and can be easily extracted from electronic health records (EHR). Please indicate the specific EHR that you use.

More on Barrett's Esophagus

Porcine Esophageal Submucosal Gland Culture Model Shows Capacity for Proliferation and Differentiation

Oct. 22, 2017

We describe a novel porcine 3-dimensional culture model that reproduces esophageal submucosal gland proliferation in vivo associated with cancer and injury.

Late Recurrence of Barrett’s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial

Sept. 1, 2017

Endoscopic surveillance of patients with BE treated with radiofrequency ablation will likely be of diminishing value as the time since ablation grows.

Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett’s Esophagus With a Minimally Invasive Cell Sampling Device

Sept. 1, 2017

We found Cytosponge screening with endoscopic confirmation to be a cost-effective strategy.